

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|----|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|----|--|

No equality issues were identified during the scoping process

- | | |
|----|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----|---|

One patient group stated the main equality issue is that ripretinib is available for treating GIST in other parts of the world (including Europe, America and Australia) but is not yet available to patients in the UK

The company noted that ripretinib has been accepted for use within NHS Scotland

The committee noted this but concluded this would not normally be considered an equalities issue for the committee to address within its recommendation.
--

- | | |
|----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----|---|

No other equality issues were identified

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the draft guidance for consultation document, and, if so, where?

Yes in section 3.16

Approved by Principal Technical Adviser: Elizabeth Bell

Date: 29th October 2025